Dry Eye Dx and Tx
Progress in Unraveling Meibomian Gland Dysfunction
By Katherine M. Mastrota, MS, OD, FAAO; Kelly K. Nichols, OD, MPH, PhD; & Gary Foulks, MD
In late 2008, the Tear Film and Ocular Surface Society (TFOS), a nonprofit organization with the primary mission of advancing research, literacy, and educational aspects of the tear film and ocular surface scientific field across the globe, initiated a workshop on meibomian gland dysfunction (MGD). More than 50 international experts participated in the effort, which occurred over a two-year period. The process was sponsored generously through industry support via unrestricted grants to TFOS, allowing volunteers to come together to create a consensus overview of the field. In addition to an exhaustive international literature-based review of the salient research, emerging concepts such as a new diagnostic and management algorithm are also included. This report, published in the March 2011 issue of Investigative Ophthalmology & Visual Science, is the most current, definitive summary of the meibomian gland in health and disease.
A two-page perforated pull-out summary of the full report, compliments of TFOS, is included in this issue of Contact Lens Spectrum. The full report can be downloaded at the TFOS website (www.tearfilm.org).
Evidence-based principles guided the preparation of the MGD Workshop report. The same evidence guidelines were used in the International Dry Eye Workshop process and are a modification of the American Academy of Ophthalmology Preferred Practice Patterns guidelines. As such, the new diagnosis and management algorithm presented in the report is an assimilation of the clinical research published to date.
It is important to note that evidence on management of MGD is somewhat limited, the existing studies are often relatively small and are neither randomized nor placebo-controlled, and most management and therapeutic techniques are used off-label. Thus, the recommendations reported here likely will continue to undergo evaluation in both clinical practice and clinical research.
Key Clinical Findings
MGD may be the most common cause of evaporative dry eye and may also have some association with aqueous-deficient dry eye. Therefore, a complete dry eye examination should include symptom evaluation, clinical assessment of the meibomian glands, meibomian gland expressibility, and evaluation of the quality of meibomian gland secretions. Co-existing dry eye should be evaluated through assessment of tear film instability and ocular surface staining. It is our hope that this report will motivate clinicians to look at the meibomian glands more closely, as well as inspire future research with the ultimate goal of improving care of MGD and dry eye patients.
The eyecare community at large receives with excitement the Meibomian Gland Workshop Report. A momentous undertaking of TFOS, it will serve as a superlative resource for clinicians and researchers striving to unravel the mysteries and management of ocular surface disease. CLS
For references, please visit www.clspectrum.com/references.asp and click on document #186.
Dr. Mastrota is secretary of the newly formed Ocular Surface Society of Optometry (OSSO). She is center director at the New York Office of Omni Eye Services and is a consultant to Allergan, AMO, B+L, Inspire, Noble Vision, and Cynacon Ocusoft. You can reach her at email@example.com.
Dr. Nichols is an associate professor at the Ohio State University College of Optometry. She has current NIH funding to study dry eye in postmenopausal women in addition to research funding through Alcon, Inspire, and Pfizer. She was the chair of the steering committee for the TFOS Meibomian Gland Dysfunction workshop. Dr. Nichols is also a consultant for or has received lecture honoraria from Alcon, Allergan, Inspire, Pfizer, TearLab, Celtic, and Eleven Biotherapeutics.
Dr. Foulks is Emeritus Professor of Ophthalmology in the Department of Ophthalmology and Visual Sciences of the University of Louisville School of Medicine and a former director of the Cornea and External Disease Service at this institution. He was also assistant dean for Clinical Trial Research at the University of Louisville School of Medicine. He is a consultant for Alcon, Allergan, B+L, Eleven Biotherapeutics, Inspire, Merck, Otsuka, Pfizer, Santen, Scynexis, and TearLab; has received research funds from Alcon and Inspire; and was supported on an NIH grant.